Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies

Neural Regen Res. 2022 Mar;17(3):567-568. doi: 10.4103/1673-5374.320985.

Authors

Emanuele D'Amico¹, Aurora Zanghì¹, Carlo Avolio²

Affiliations

¹ Department "G.F. Ingrassia"; MS Center, University of Catania, Catania, Italy.
² Department of Medical and Surgical Sciences, University of Foggia; Multiple Sclerosis Center, Department of Neurosciences, Policlinico Riuniti Hospital, Foggia, Italy.

No abstract available